Jiangsu Vcare Completes Phase III Enrollment of VC005, a Next-Generation High-Selective JAK1 Inhibitor for Moderate-to-Severe Atopic Dermatitis

　　Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.

​

　　In the completed Phase Ⅱ clinical trial for moderate-to-severe AD, VC005 Tablets demonstrated significant efficacy across multiple key endpoints including EASI-75, EASI-90, and IGA 0/1. It showed immediate pruritus relief on the first day of administration, with overall good safety and tolerability. Beyond moderate-to-severe AD, clinical research on VC005 Tablets for other indications is also progressing smoothly. Recently, the company has officially initiated the Phase Ⅲ clinical study for ankylosing spondylitis (AS) and the Phase Ⅱ clinical trial for non-segmental vitiligo (NSV), gradually building a comprehensive layout in the field of autoimmune diseases.

​

　　In August 2025, Jiangsu Vcare entered into an exclusive commercialization cooperation agreement with Huadong Medicine for VC005 Tablets, further highlighting the market potential of the project.

About VC005

　　VC005 Tablets is a novel, potent, and highly selective second-generation JAK1 inhibitor, for which Jiangsu Vcare holds independent intellectual property rights. In August 2025, Jiangsu Vcare entered into an exclusive strategic cooperation with Huadong Medicine regarding the commercialization rights of VC005 Tablets in Mainland China. By selectively inhibiting JAK1, VC005 Tablets reduces inflammatory responses and the activation of immune cells. Currently, the molecule has been developed for multiple autoimmune diseases such as moderate-to-severe atopic dermatitis, ankylosing spondylitis, rheumatoid arthritis, and vitiligo, with two dosage forms under development: oral tablets and topical gel. While maintaining strong JAK1 inhibitory activity, VC005 Tablets further reduces JAK2 inhibitory activity in a selective manner (based on in vitro kinase assay results), which is expected to alleviate safety issues caused by excessive JAK2 inhibition in clinical practice.

About Atopic Dermatitis​

　　Atopic Dermatitis (AD) is a chronic, recurrent, inflammatory skin disease, mainly characterized by dry skin, intense pruritus, and eczematous rashes, which severely affects patients' quality of life. In terms of epidemiology, the total number of patients worldwide is approximately 230 million. The prevalence of AD among adults in China is about 2% to 8%, with the number of patients exceeding 70 million. Among them, moderate to severe cases account for 33%, and the patient population shows a continuous upward trend. Currently, in terms of therapeutic drugs, traditional oral medications for AD have many adverse reactions and poor efficacy, making it difficult to achieve effective and stable control of the disease. In contrast, the second-generation highly selective oral JAK1 small-molecule targeted inhibitors can not only control the condition effectively but also take effect quickly, achieve long-term patient response, and have good safety, thus providing a better medication option for patients with moderate to severe AD.​